2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

PI3

" in MedChemExpress (MCE) Product Catalog:

1131

Inhibitors & Agonists

12

Screening Libraries

1

Fluorescent Dye

17

Biochemical Assay Reagents

24

Peptides

9

Inhibitory Antibodies

257

Natural
Products

8

Recombinant Proteins

58

Isotope-Labeled Compounds

34

Antibodies

17

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144806
    PI3K/AKT-IN-1
    10+ Cited Publications

    		 PI3K Akt Apoptosis Cancer
    PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis .
    PI3K/AKT-IN-1
  • HY-111508
    PI3K/mTOR Inhibitor-2
    1 Publications Verification

    		 PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR . Antitumor activity .
    PI3K/mTOR Inhibitor-2
  • HY-146751
    PI3K/Akt/mTOR-IN-2
    4 Publications Verification

    		 PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis .
    PI3K/Akt/mTOR-IN-2
  • HY-111570
    PI3Kγ inhibitor AZ2
    2 Publications Verification

    		 PI3K Inflammation/Immunology
    PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3). PI3Kγ inhibitor AZ2 can be used for the research of inflammatory and immune diseases .
    PI3Kγ inhibitor AZ2
  • HY-143404
    PI3K-IN-30
    3 Publications Verification

    		 PI3K Cancer
    PI3K-IN-30 (compound 6d) is a potent PI3K inhibitor with IC50s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively .
    PI3K-IN-30
  • HY-151622
    PI3K/mTOR Inhibitor-11
    2 Publications Verification

    		 PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-11 is an orally active PI3K/mTOR inhibitor (IC50: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .
    PI3K/mTOR Inhibitor-11
  • HY-10620
    PI3K-IN-22

    		PI3K mTOR Cancer
    PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC50s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .
    PI3K-IN-22
  • HY-128333
    PI3K/mTOR Inhibitor-4

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-4 is an orally active pan-class I PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-4 has enzymatic inhibition activity for PI3Kα, PI3Kγ, PI3Kδ and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM and 13.85 nM, respectively. PI3K/mTOR Inhibitor-4 can be used for the research of cancer .
    PI3K/mTOR Inhibitor-4
  • HY-150618
    PI3Kα-IN-9
    1 Publications Verification

    		 PI3K Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    PI3Kα-IN-9 (compound 27) is a selective, long-acting and oral active PI3Kα inhibitor with IC50 values of 4.4, 128, 146 and 153 nM for PI3Kα, PI3Kγ, PI3Kδ and PI3Kβ, respectively. PI3Kα-IN-9 has antiproliferative activity and induces apoptosis. PI3Kα-IN-9 can be used for cancer research .
    PI3Kα-IN-9
  • HY-153120A
    PI3K/mTOR Inhibitor-13 sodium

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
    PI3K/mTOR Inhibitor-13 sodium
  • HY-147284
    PI3K-IN-37

    		PI3K mTOR Others
    PI3K-IN-37 (Example 84.1) is a PI3K α/β/δ inhibitor with IC50s of 6, 8, 4 nM, respectively. PI3K-IN-37 can also inhibit mTOR (IC50=4 nM) .
    PI3K-IN-37
  • HY-131345
    PI3Kα-IN-4

    		PI3K Cancer
    PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity .
    PI3Kα-IN-4
  • HY-RS10463
    PI3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    PI3 Human Pre-designed siRNA Set A contains three designed siRNAs for PI3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PI3 Human Pre-designed siRNA Set A
    PI3 Human Pre-designed siRNA Set A
  • HY-143403
    PI3K-IN-31

    		PI3K Cancer
    PI3K-IN-31 (Compound 6b) is a potent PI3K inhibitor with IC50s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31 has anticancer effects .
    PI3K-IN-31
  • HY-176854
    PI3K/mTOR-IN-18

    		PI3K mTOR Cancer
    PI3K/mTOR-IN-18 (Compound 12) is a highly selective dual PI3K/mTOR inhibitor. PI3K/mTOR-IN-18 shows antitumor effects via competitive binding to PI3Kα (Ki=0.130 nM) and mTOR (Ki=0.111 nM). PI3K/mTOR-IN-18 blocks the PI3K/AKT/mTOR pathway and inhibits tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is promising for research of solid tumors (e.g., breast, NSCLC) .
    PI3K/mTOR-IN-18
  • HY-147768
    PI3K/AKT-IN-2

    		PI3K Akt Microtubule/Tubulin MMP Apoptosis Cancer
    PI3K/AKT-IN-2 (Compound 12c) is a PI3K and AKT inhibitor. PI3K/AKT-IN-2 blocks the epithelial-mesenchymal transition (EMT) and induces apoptosis. PI3K/AKT-IN-2 inhibits the polymerization of tubulin .
    PI3K/AKT-IN-2
  • HY-109633
    PI3K/mTOR-IN-23

    		mTOR PI3K Cancer
    PI3K/mTOR-IN-23 is a dual inhibitor of PI3K and mTOR with IC50 values of 49 and 41 nM. PI3K/mTOR-IN-23 inhibits cancer cells proliferation .
    PI3K/mTOR-IN-23
  • HY-142676
    PI3K-IN-26

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1) .
    PI3K-IN-26
  • HY-153120
    PI3K/mTOR Inhibitor-13

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
    PI3K/mTOR Inhibitor-13
  • HY-174798
    PI3Kα Ligand-1

    		PI3K Ligands for Target Protein for PROTAC Cancer
    PI3Kα Ligand-1 is the ligand for PI3Kα that can be used for synthesis of PROTACs, such as PI3Kα degrader-1 (HY-174461) .
    PI3Kα Ligand-1
  • HY-150309
    PI3K-IN-54

    		PI3K Cancer
    PI3K-IN-54 (compound 10w) is a pan-PI3K inhibitor. The IC50 values of PI3K-IN-54 for p110α, p110β, and p110δ are 0.22 nM, 1.4 nM, and 0.38 nM, respectively. PI3K-IN-54 can be used in cancer research .
    PI3K-IN-54
  • HY-112602
    PI3K/mTOR Inhibitor-1

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively . Antitumor activity .
    PI3K/mTOR Inhibitor-1
  • HY-109633A
    PI3K/mTOR-IN-23 dihydrochloride

    		mTOR PI3K Cancer
    PI3K/mTOR-IN-23 dihydrochloride is a dual inhibitor of PI3K and mTOR with IC50 values of 49 and 41 nM. PI3K/mTOR-IN-23 dihydrochloride inhibits cancer cells proliferation .
    PI3K/mTOR-IN-23 dihydrochloride
  • HY-179155
    PI3K/mTOR-IN-19

    		PI3K mTOR Apoptosis Bcl-2 Family MDM-2/p53 Telomerase Mitochondrial Metabolism Inflammation/Immunology Cancer
    PI3K/mTOR-IN-19 is an orally active, potent, selective PI3K (IC50 = 4.23 nM) and mTOR (IC50 = 2.3 nM) inhibitor. PI3K/mTOR-IN-19 significantly inhibits Eca109 cell viability and induces apoptosis. PI3K/mTOR-IN-19 causes G0/G1 cell cycle arrest, decreased mitochondrial membrane potential, and demonstrates marked telomerase inhibitory activity. PI3K/mTOR-IN-19 modulates the expression of key apoptotic regulators (Bcl-2, Bax, and p53) and downregulates the PI3K/Akt/mTOR signaling pathway. PI3K/mTOR-IN-19 can be used for the study of esophageal cancer .
    PI3K/mTOR-IN-19
  • HY-142677
    PI3K-IN-27

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .
    PI3K-IN-27
  • HY-125376
    PI3Kδ-IN-3

    		PI3K Cancer
    PI3Kδ-IN-3 (Compound 11) is a PI3Kδ inhibitor (IC50: 9 nM). PI3Kδ-IN-3 inhibits B cell function. PI3Kδ-IN-3 has good pharmacokinetic properties .
    PI3Kδ-IN-3
  • HY-175369
    PI3Kδ-IN-25

    		PI3K Akt PD-1/PD-L1 Interleukin Related CD3 Inflammation/Immunology Cancer
    PI3Kδ-IN-25 is an orally active selective PI3Kδ inhibitor (IC50 = 2.1 nM). PI3Kδ-IN-25 has IC50s of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. PI3Kδ-IN-25 inhibits AKT Ser473 phosphorylation, suppresses Treg cell proliferation, and downregulates PD-L1 expression in B16F10 cells. PI3Kδ-IN-25 exhibits anticancer effects in B16F10 melanoma and Lewis lung cancer mouse models by reducing tumor-infiltrating Treg cells and enhancing immune responses. PI3Kδ-IN-25 is potentially useful in the study of melanoma, lung cancer, and other cancers .
    PI3Kδ-IN-25
  • HY-147898
    PI3K-IN-33

    		PI3K Apoptosis Cancer
    PI3K-IN-33 (Compound 6e) is a highly selective PI3K inhibitor with IC50 values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-33 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-33 can be used in leukemia research .
    PI3K-IN-33
  • HY-147900
    PI3K-IN-35

    		PI3K Apoptosis Cancer
    PI3K-IN-35 (Compound 6l) is a highly selective PI3K inhibitor with IC50 values of 13.98, 7.22 and 10.94 μM for PI3K-α、PI3K-β and PI3K-δ, respectively. PI3K-IN-35 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-35 can be used in leukemia research .
    PI3K-IN-35
  • HY-147899
    PI3K-IN-34

    		PI3K Apoptosis Cancer
    PI3K-IN-34 (Compound 6g) is a highly selective PI3K inhibitor with IC50 values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-34 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-34 can be used in leukemia research .
    PI3K-IN-34
  • HY-121672
    PI3K-IN-7

    		PI3K Akt Apoptosis Cancer
    PI3K-IN-7 (Compound C96) is a PI3K inhibitor. PI3K-IN-7 inhibits phosphorylation of AKT and the activation of an AKT downstream protein. PI3K-IN-7 induces apoptosis of the tumor cells. PI3K-IN-7 has low toxicity for normal cells. PI3K-IN-7 can be used for research of acute and chronic leukemia, multiple myeloma, lymphoma .
    PI3K-IN-7
  • HY-144450
    PI3K-IN-29

    		PI3K Akt Cancer
    PI3K-IN-29 is a potent PI3K inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively. PI3K-IN-29 inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K .
    PI3K-IN-29
  • HY-149521
    PI3K-IN-47

    		PI3K Cancer
    PI3K-IN-47 (Compound 27) is a bivalent PI3K inhibitor (IC50: 0.44 nM for PI3Kα, 7.18 nM, 13.92 nM, 22.83 nM for PI3Kβ, PI3Kγ, PI3Kδ). PI3K-IN-47 induces cell cycle arrest in G1 phase, inhibits colony formation and cell migration. PI3K-IN-47 inhibits tumor growth in HGC-27 xenograft mice .
    PI3K-IN-47
  • HY-150034
    PI3K-IN-38

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-38 (compound 123) is an orally active PI3K inhibitor with IC50 of 0.541 µM (PI3K-α). PI3K-IN-38 shows activities of anticancer and anti-inflammatory, which inhibis tumor growth in vivo .
    PI3K-IN-38
  • HY-150019
    PI3K-IN-36

    		PI3K Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    PI3K-IN-36 (compound A68) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL) .
    PI3K-IN-36
  • HY-155730
    PI3K-IN-41

    		PI3K Cancer
    PI3K-IN-41 (compound 2) is a photocaged compound, as well as a photocaged PI3K inhibitor (IC50=18.92 nM) with anticancer properties. PI3K-IN-41 has potential to be used in precisely controlled cancer therapeutics. PI3K-IN-41 exhibits potent PI3K ihibition upon UV light irradiation, and enhances antitumor effect .
    PI3K-IN-41
  • HY-147613
    PI3K/mTOR Inhibitor-6

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of PI3K/mTOR. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .
    PI3K/mTOR Inhibitor-6
  • HY-161852
    PI3K-IN-55

    		PI3K Apoptosis Cancer
    PI3K-IN-55 (Compound 6a) is a potent inhibitor for PI3K. PI3K-IN-55 affects PI3K/Akt/p53 signaling pathway, inhibits the proliferation of cancer cells A549, Hela, HepG2, MCF-7 and HT-29, with IC50s of 1.03-6.78 μM. PI3K-IN-55 induces apoptosis in cell MCF-7 .
    PI3K-IN-55
  • HY-136806
    PI3K-IN-12

    		PI3K Cancer
    PI3K-IN-12 (comp 76) is a PI3K inhibitor .
    PI3K-IN-12
  • HY-152238
    PI3K/mTOR Inhibitor-12

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-12 is a potent, orally active and selective PI3K/mTOR inhibitor with IC50 values of 0.06 nM and 3.12 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-12 has antitumor activity. PI3K/mTOR Inhibitor-12 has lower liver toxicity .
    PI3K/mTOR Inhibitor-12
  • HY-108418
    PI3Kδ-IN-15
    1 Publications Verification

    		 PI3K Cancer
    PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC50 of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .
    PI3Kδ-IN-15
  • HY-103030
    PI3K-IN-32

    		PI3K Cancer
    PI3K-IN-32 is an imidazopyridine derivative with a 3-NH2 substituent, and also a PI3K p110α inhibitor. PI3K-IN-32 is applicable for cancer research .
    PI3K-IN-32
  • HY-134472
    PI3Kδ-IN-8

    		PI3K Cancer
    PI3Kδ-IN-8 is a potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 3.3 nM. PI3Kδ-IN-8 shows selectivity for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50=377.2, 241.6, 17.9 nM, respectively). PI3Kδ-IN-8 has anti-tumor activity .
    PI3Kδ-IN-8
  • HY-171558
    PI3K-IN-56

    		PI3K Akt Cancer
    PI3K-IN-56 (Compound 1) is an orally active, potent and selective irreversible inhibitor of phosphoinositide 3-kinase (PI3K). PI3K-IN-56 irreversibly blocks the phosphatidylinositol-3,4,5-triphosphate (PIP3) production and downstream AKT signaling pathway. PI3K-IN-56 is promising for research of PI3Kα-driven cancers, such as breast and ovarian cancers .
    PI3K-IN-56
  • HY-156080
    PI3K-IN-48

    		PI3K Akt Cancer
    PI3K-IN-48 is a PI3K inhibitor with IC50 value of 1.55 ± 0.18 μM for A549 cells. PI3K-IN-48 can induce G0/G1 phase arrest, cell apoptosis, and down-regulate expression of p-PI3K and p-Akt. PI3K-IN-48 can be used for human lung cancers diseases research .
    PI3K-IN-48
  • HY-145432
    PI3K-IN-28

    		PI3K Cancer
    PI3K-IN-28 (Compound 6c) is a potent inhibitor of PI3K. PI3K-IN-28 displays the most potent activity with lower toxic effects on MCF-10a. PI3K-IN-28 displays half-maximal inhibitory concentration (IC50, μM) values of 5.8, 2.3, and 7.9. PI3K-IN-28 is the most potent one with a selectivity index (SI) of 39 and is considered as a latent lead for further optimization of anticancer agents .
    PI3K-IN-28
  • HY-146159
    PI3K/HDAC-IN-2

    		PI3K HDAC Cancer
    PI3K/HDAC-IN-2 is a potent dual PI3K/HDAC inhibitor with IC50s of 226 nM, 279 nM, 467 nM, 29 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, respectively, and IC50s of 1.3 nM, 3.4 nM, 972 nM, 17 nM, 12 nM for HDAC1, HDAC2, HDC4, HDAC6, HDAC8, respectively. PI3K/HDAC-IN-2 exhibits PI3Kδ and class I and IIb HDAC selectivity. PI3K/HDAC-IN-2 has remarkable anticancer effects .
    PI3K/HDAC-IN-2
  • HY-147614
    PI3K/mTOR Inhibitor-7

    		PI3K mTOR Cancer
    PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of PI3K/mTOR. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC50 values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .
    PI3K/mTOR Inhibitor-7
  • HY-160282
    PI3K-IN-49

    		PI3K Cancer
    PI3K-IN-49 is a potent PI3K inhibitor. PI3K-IN-49 shows antiproliferative activity for Avg T-47D and Avg SKBR3 cells (WO2023239710A1; example 29) .
    PI3K-IN-49
  • HY-161301
    PI3K-IN-52

    		PI3K Cancer
    PI3K-IN-52 (compound cis 6g) is a potent inhibitor of PI3K, with IC50 of 0.23 μM in HGC-27 cells. PI3K-IN-52 plays an important role in cancer research[1].
    PI3K-IN-52

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: